Trials / Completed
CompletedNCT00247247
Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.
Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- —
Summary
Multi-centre, randomised, parallel-group study, rater-blinded. Total duration of the study per subject is 12 weeks plus a one- to two-week screening period. There are 6 pre-planned visits per subject: screening visit followed by 5 visits. Approximately 300 patients altogether in up to 25 active German study centres and up to 3 active Lithuanian study centres will be randomised.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Comtess® |
Timeline
- Start date
- 2002-12-01
- Completion
- 2005-06-01
- First posted
- 2005-11-01
- Last updated
- 2007-06-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00247247. Inclusion in this directory is not an endorsement.